[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0712273A8 - anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit - Google Patents

anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit

Info

Publication number
BRPI0712273A8
BRPI0712273A8 BRPI0712273A BRPI0712273A BRPI0712273A8 BR PI0712273 A8 BRPI0712273 A8 BR PI0712273A8 BR PI0712273 A BRPI0712273 A BR PI0712273A BR PI0712273 A BRPI0712273 A BR PI0712273A BR PI0712273 A8 BRPI0712273 A8 BR PI0712273A8
Authority
BR
Brazil
Prior art keywords
hepsin
disease
antibody
methods
diagnose
Prior art date
Application number
BRPI0712273A
Other languages
English (en)
Inventor
K Kirchhofer Daniel
Vij Rajesh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0712273A2 publication Critical patent/BRPI0712273A2/pt
Publication of BRPI0712273A8 publication Critical patent/BRPI0712273A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucleico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit <um>resumo<mv> são fornecidos anticorpos monoclonais anti-hepsina e métodos para uso dos mesmos.
BRPI0712273A 2006-06-22 2007-06-20 anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit BRPI0712273A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80558906P 2006-06-22 2006-06-22
US60/805,589 2006-06-22
PCT/US2007/071688 WO2007149932A2 (en) 2006-06-22 2007-06-20 Methods and compositions for targeting hepsin

Publications (2)

Publication Number Publication Date
BRPI0712273A2 BRPI0712273A2 (pt) 2012-03-06
BRPI0712273A8 true BRPI0712273A8 (pt) 2019-01-22

Family

ID=38754528

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712273A BRPI0712273A8 (pt) 2006-06-22 2007-06-20 anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit

Country Status (16)

Country Link
US (2) US8124352B2 (pt)
EP (1) EP2044124A2 (pt)
JP (1) JP2009540835A (pt)
KR (1) KR101410195B1 (pt)
CN (1) CN101490088B (pt)
AU (1) AU2007260950B2 (pt)
BR (1) BRPI0712273A8 (pt)
CA (1) CA2656168A1 (pt)
IL (1) IL195561A (pt)
MX (1) MX2008015882A (pt)
MY (1) MY150643A (pt)
NO (1) NO20090333L (pt)
NZ (1) NZ573178A (pt)
RU (1) RU2009101813A (pt)
WO (1) WO2007149932A2 (pt)
ZA (1) ZA200810225B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831370A4 (en) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES PARTICIPATING IN BONE REMODELING
KR101410195B1 (ko) 2006-06-22 2014-06-19 제넨테크, 인크. 헵신을 표적화하기 위한 방법 및 조성물
AR078716A1 (es) 2009-10-22 2011-11-30 Genentech Inc Anticuerpos antihepsina y metodos para su uso
WO2011050194A1 (en) * 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
PL2542576T3 (pl) * 2010-03-02 2016-10-31 Sposoby badań przesiewowych przeciwciał
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
LT3415531T (lt) * 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2017162659A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Intracellular hepsin as therapeutic target for the treatment of cancer with centrosome amplification

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6268165B1 (en) 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
JP2003521920A (ja) 2000-02-03 2003-07-22 コルバス・インターナショナル・インコーポレイテッド 膜貫通セリンプロテアーゼをコードしている核酸分子、コードされたタンパク質、およびそれらに基づく方法
US6423543B1 (en) 2000-12-20 2002-07-23 Isis Pharmaceuticals, Inc. Antisense modulation of hepsin expression
WO2002059373A2 (en) 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
AU2002240336A1 (en) 2001-02-14 2002-08-28 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US6482630B2 (en) 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
AU2002335640A1 (en) * 2001-08-17 2003-03-03 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
AU2003225540A1 (en) 2002-01-31 2003-09-02 Irm, Llc Hepsin substrates and prodrugs
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP3775346B2 (ja) * 2002-05-29 2006-05-17 株式会社日立製作所 テレビ電話システムおよびその端末装置
WO2004009803A2 (en) 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation of human hepsin
US6977170B2 (en) 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
JP2006507813A (ja) * 2002-10-04 2006-03-09 シエーリング アクチエンゲゼルシャフト 置換体活性化配列を有する修飾されたヘプシン分子及びその使用
JP5226308B2 (ja) 2004-07-26 2013-07-03 ジェネンテック， インコーポレイテッド 肝細胞増殖因子活性化を制御するための方法及び組成物
KR101410195B1 (ko) 2006-06-22 2014-06-19 제넨테크, 인크. 헵신을 표적화하기 위한 방법 및 조성물
US20100061996A1 (en) * 2006-06-22 2010-03-11 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
AR078716A1 (es) * 2009-10-22 2011-11-30 Genentech Inc Anticuerpos antihepsina y metodos para su uso

Also Published As

Publication number Publication date
BRPI0712273A2 (pt) 2012-03-06
CN101490088A (zh) 2009-07-22
AU2007260950B2 (en) 2011-09-15
KR20090029276A (ko) 2009-03-20
JP2009540835A (ja) 2009-11-26
NO20090333L (no) 2009-03-23
EP2044124A2 (en) 2009-04-08
IL195561A0 (en) 2011-08-01
AU2007260950A1 (en) 2007-12-27
US20120141374A1 (en) 2012-06-07
NZ573178A (en) 2012-02-24
KR101410195B1 (ko) 2014-06-19
US8124352B2 (en) 2012-02-28
IL195561A (en) 2013-04-30
WO2007149932A3 (en) 2008-05-02
CA2656168A1 (en) 2007-12-27
WO2007149932A2 (en) 2007-12-27
CN101490088B (zh) 2015-04-08
ZA200810225B (en) 2010-03-31
AU2007260950A8 (en) 2009-01-22
RU2009101813A (ru) 2010-07-27
US8383123B2 (en) 2013-02-26
MY150643A (en) 2014-02-14
MX2008015882A (es) 2009-01-12
US20100021474A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
BRPI0712273A8 (pt) anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
BRPI0820885B8 (pt) &#34;anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)&#34;.
ES2636483T3 (es) Métodos y sistemas para la amplificación de señal de bioensayos
EP2332988A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
BRPI0812875A2 (pt) &#34; método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste &#34;.
CN101358969A (zh) 用单一特异性捕获剂定量检测分析物的新方法
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
ES2803217T3 (es) Antígeno de superficie de células de cáncer de próstata para el diagnóstico
ES2627482T3 (es) Procedimiento para la detección de una proteína de unión multiespecífica
WO2007098297A3 (en) Method for diagnosing and treating kidney cancer
WO2007111875A3 (en) Methods for diagnosing and treating kidney and colorectal cancer
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
BRPI0915667A2 (pt) ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, método de tratamento, antiligante, método de detecção do antiligante em uma amostra biológica, kit de imunoesaio para detecção do antiligante, uso do kit de imunoensaio
ATE474857T1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
FR2900936B1 (fr) Procede et methodes de detection de la maladie d&#39;alzheimer
JP4700626B2 (ja) 分子上のエピトープの免疫検出のための試薬、キット及び方法
FI3523653T3 (fi) Rep-proteiini proteiiniantigeenina käytettäväksi diagnostisissa määrityksissä
RU2018138782A (ru) Антитела к фактору ix padua
RU2011140006A (ru) Способ детекции вещества в биологическом образце
DE60138192D1 (de) Verfahren zur quantifizierung der akt-protein-expression
WO2023209687A1 (en) Cas9 antibodies and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]